Published in final edited form as:

Bioorg Med Chem Lett. 2009 December 1; 19(23): 6755–6758. doi:10.1016/j.bmcl.2009.09.099.

A new approach to the synthesis of polyunsaturated deuterated isoprostanes: Total synthesis of d_4 -5-*epi*-8,12-*iso*-iPF_{3 α} -VI and d_4 -8,12-*iso*-iPF_{3 α} -VI

Chih-Tsung Chang^a, Pranav Patel^a, Vivek Gore^a, Wen-Liang Song^b, John A. Lawson^b, William S. Powell^c, Garret A. FitzGerald^b, and Joshua Rokach^a

^a Claude Pepper Institute and Department of Chemistry, Florida Institute of Technology, 150 W. University Blvd., Melbourne, FL 32901, USA

^b Institute for Translational Medicine and Therapeutics and Department of Pharmacology, University of Pennsylvania, Philadelphia, PA 19104, USA

^c Meakins-Christie Laboratories, Department of Medicine, McGill University, 3626 St. Urbain Street, Montreal, QC, H2X 2P2, Canada

Abstract

The total and stereospecific synthesis of d_4 -5-*epi*-8,12-*iso*-iPF_{3 α} -VI **55** and d_4 -8,12-*iso*-iPF_{3 α} -VI **64**, EPA-derived all-*syn*-isoprostanes (iPs), has been accomplished. Because of issues related to volatility and yield with some of the primary deuterated synthons an improved synthesis is presented. These two deuterated analogs were used to discover and quantify the presence of the corresponding endogenous isoprostanes in human urine. These assays may serve as a valuable index of oxidative stress in population with omega-3 fatty acid enriched diets containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and may also be useful as an index of the severity of inflammatory diseases such as atherosclerosis and Alzheimer's disease.

Isoprostanes (iPs) are natural products of non-enzymatic free radical peroxidation of polyunsaturated fatty acids (PUFAs) such as arachidonic acid (AA) and eicosapentaenoic acid (EPA).^{1,2} Isoprostanes are isomeric with prostaglandins (PGs), which are natural products generated by the action of enzymes. The mechanisms of formation of isoprostanes have been discussed in some detail.³⁻⁵ Several syntheses of iPs have been reported.^{3,6} These compounds have been widely used as markers of oxidative stress in various diseases. We and others have shown that the measurement of iPs in urine can be used as an index of the severity of inflammatory diseases such as Alzheimer's disease (AD) and atherosclerosis.^{2,7}

Isoprostanes generated from EPA have received less attention than AA-derived isoprostanes.^{8,9} However, the AA-derived iPs we and others have measured so far as an index of oxidative stress¹⁰⁻¹² may not be appropriate for individuals in which the major PUFAs in the phospholipids are EPA and DHA. A more appropriate index in these cases might be the measurement of EPA- and/or DHA-derived iPs, e.g. **24** and **25** (Scheme 2A). For these reasons we have synthesized these two all-*syn* Group VI isoprostanes and identified their occurrence

© 2009 Elsevier Ltd. All rights reserved.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

in human urine.¹³ The reason for choosing Group VI isoprostanes derived from EPA stems from our experience that the presence of a hydroxyl group in the 5-position of these iPs causes them to be resistant to β -oxidation,⁸ facilitating their detection in urine. For example, we have shown that iPF_{3 α} -VI is highly resistant to β -oxidation and we have been able to detect appreciable amounts of this substance in human urine.⁸ Recent studies from our laboratory suggest that 5-*epi*-8,12-*iso*-iPF_{3 α} -VI **24** and 8,12-*iso*-iPF_{3 α} -VI **25** are considerably more abundant in urine than iPF_{3 α} -VI and may therefore serve as excellent markers for oxidative stress involving degenerative diseases of the brain, which contains high levels of DHA, as well as in individuals who consume large amounts of ω 3-PUFA. To provide the deuterium-labeled standards required for the quantitation of these major EPA-derived iPs in biological fluids¹⁴ we are reporting here the total synthesis of deuterated analogs of **24** and **25**, namely d₄-5-*epi*-8,12-*iso*-iPF_{3 α} -VI **55** and d₄-8,12-*iso*-iPF_{3 α} -VI **64** (Scheme 4).

Site of deuteration

We have previously developed methods to introduce four deuterium atoms into the lower side chains of iPs, as this would avoid the loss of deuterium as a result of β -oxidation. Although this is much less of an issue with Group VI iPs, as discussed above, there is an additional advantage in avoiding the addition of deuterium to the upper side chain due to the risk of scrambling in the synthetic oxo precursors of this side chain. Because of the presence of the ω 3-double bond in **24** and **25**, we elected to introduce four deuterium atoms in positions 19 and 20 of these molecules.

Synthesis

The most difficult step in our prior synthesis of tetradeutero iPF_{4 α} -VI was the isolation of deuterated propanol **32** (Scheme 3).¹⁵ The continuation of the synthesis to obtain derivative **38** was impractical at that point because of the dwindling yields due to the multistep synthesis. We elected at that time to redesign the synthesis by extending the isoprostane synthon by three additional carbons and reacting it with deuterated synthon **35**.¹⁵ This was hardly a fruitful alternative since the isoprostane synthon requires a multistep synthesis, making the synthesis completely linear rather than convergent, which was our original intention.

In the present study we circumvented the volatility issue in two ways. We used a non-volatile tosylate intermediate and a very efficient procedure to convert a tosylate phosphonium salt into an iodide derivative, as the use of the phosphonium tosylate by itself results in low yields in a Wittig reaction. Transformation of tosylate salts **34** and **40** to iodides **35** and **41**, respectively, proceeds in quantitative yields. We were surprised to note that the literature does not contain examples of such transformations. This can be a useful general procedure to deal with deuterium labeled small molecules.

Scheme 3 describes the synthesis of the deuterated side chain, which was subsequently connected to the 5-membered all-*syn* isoprostane ring. Using commercial propargyl alcohol as our starting material, the alcohol was protected using THP. The acetylene derivative **30** (Scheme 3) was then treated with Wilkinson's catalyst in the presence of deuterium gas to generate the deuterated intermediate **31**, which on further treatment with dimethyl aluminum chloride generated the low-boiling volatile three-carbon alcohol **32**. Attempts to isolate this alcohol resulted in very low recovery. The crude **32**, which was used without purification or workup in the next step, was treated with TsCl to generate tosylate **33**. After workup and purification, **33** was treated with triphenyl phosphine in the presence of CH₃CN to generate the phosphonium salt **34**, which was purified by column chromatography. We attempted to react **34** with aldehyde **36** and obtained a low yield of the desired product **37** (22-38%). By changing the tosylate to an iodide using sodium iodide, we obtained the iodo phosphonium salt **35**.¹⁶ This was then used in a Wittig reaction with aldehyde **36** to obtain the desired product

in 85% isolated yield. A cursory look at the literature reveals that tosylate salts, when used in Wittig reactions, afford low yields of the desired products. It is worth mentioning that an attempt to prepare the tetradeutero propyl iodide from **32** resulted in very low yield of the iodo derivative, probably due to volatility problems. As shown in Scheme 3, phosphonium salt **41** was prepared in good yield by a similar sequence (Panel B). Scheme 4 describes the stereospecific synthesis of d₄-5-*epi*-8,12-*iso*-iPF_{3α}-VI **55** and d₄-8,12-*iso*-iPF_{3α}-VI **64**.¹⁷ For reasons of clarity we have included the first few structures, which we have previously disclosed.¹⁵ Step u, Scheme 4B afforded in addition to the desired product **60**, 8-9% of the *cis* derivative **59**. The isomerization procedure works well also on the crude mixture and no special purification and isolation of **59** is necessary. The transformation of bis-TES **56** to a TES aldehyde **57** was accomplished in high yields using Spur's procedure.¹⁸

Metabolism

The iPs **24** and **25** (Scheme 2) can be formed by the direct autooxidation of EPA as shown in Scheme 1. Alternatively, these iPs can be formed as a result of β-oxidation of DHA-derived neuroprostanes (nPs) as shown in Scheme 5, which we have previously demonstrated in the case of isomers of **65**.⁸ Furthermore we and others have shown the DHA-derived nPs could not be detected in urine, a fact we interpreted as being due to β-oxidation.^{8,9} Since iPs such as **24** and **25** are resistant to β-oxidation we were readily able to measure them in urine. Hence the measurement of **24** and **25**, which we have accomplished in human and murine urine,¹⁴ is an indication of the *in vivo* formation of either or both EPA-derived iPs and DHA-derived nPs that have been converted to the corresponding C₂₀ derivatives by endogenous β-oxidation.

Acknowledgments

We wish to acknowledge the National Institutes of Health for support under Grants HL-81873 (J.R.) and HL-62250 (G.A.F.). J.R. also wishes to acknowledge the National Science Foundation for the AMX-360 (CHE-90-13145) and Bruker 400 MHz (CHE-03-42251) NMR instruments. G.A.F. is the McNeil Professor of Translational Medicine and Therapeutics. W.S.P. wishes to acknowledge the Canadian Institutes of Health Research, grant number MOP-6254, the Heart and Stroke Foundation of Quebec, and the J.R. Costello Memorial Research Fund. W.S. wishes to acknowledge the AHA grant 09CRP2260567.

References and Notes

- Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ II. Proc. Natl. Acad. Sci. USA 1990;87:9383. [PubMed: 2123555]
- Lawson JA, Rokach J, FitzGerald GA. J. Biol. Chem 1999;274:24441. [PubMed: 10455102]
- Hwang SW, Adiyaman M, Khanapure S, Schio L, Rokach J. J. Am. Chem. Soc 1994;116:10829.
- Rokach J, Khanapure SP, Hwang SW, Adiyaman M, Schio L, FitzGerald GA. Synthesis, First Special Issue, Natural Products Synthesis 1998:569.
- Yin H, Havrilla CM, Gao L, Morrow JD, Porter NA. J. Biol. Chem 2003;278:16720. [PubMed: 12609993]
- (a) Pudukulathan Z, Manna S, Hwang SW, Khanapure SP, Lawson JA, FitzGerald GA, Rokach J. J. Am. Chem. Soc 1998;120:11953. (b) Jacobo SH, Chang CT, Lee GJ, Lawson JA, Powell WS, Pratico D, FitzGerald GA, Rokach J. J. Org. Chem 2006;71:1370. [PubMed: 16468784] (c) Taber DF, Herr RJ, Gleave DM. J. Org. Chem 1997;62:194. [PubMed: 11671381] (d) Taber DF, Xu M, Hartnett JC. J. Am. Chem. Soc 2002;124:13121. [PubMed: 12405840] (e) Larock RC, Lee NH. J. Am. Chem. Soc 1991;113:7815. (f) Zanoni G, Fabio A, Meriggi A, Vidari G. Tetrahedron: Asymmetry 2001;12:1779. (g) Schrader TO, Snapper ML. J. Am. Chem. Soc 2002;124:10998. [PubMed: 12224945] (h) Quan LG, Cha JK. J. Am. Chem. Soc 2002;124:12424. [PubMed: 12381179] (i) Rodriguez AR, Spur BW. Tetrahedron Lett 2002;43:4575. (j) Mulzer J, Czybowski M, Bats JW. Tetrahedron Lett 2001;42:2961.
- Montine TJ, Neely DM, Quinn JF, Beal FM, Markesbery WR, Roberts LJ II, Morrow JD. Free Radic. Biol. Med 2002;33:620. [PubMed: 12208348]

8. Lawson JA, Kim S, Powell WS, FitzGerald GA, Rokach J. J. Lipid Res 2006;47:2515. [PubMed: 16943517]
9. Gao L, Yin H, Milne GL, Porter NA, Morrow JD. J. Biol. Chem 2006;281:14092. [PubMed: 16569632]
10. Kadiiska MB, Gladen BC, Baird DD, Germolec D, Graham LB, Parker CE, Nyska A, Wachsman JT, Ames BN, Basu S, Brot N, FitzGerald GA, Floyd RA, George M, Heinecke JW, Hatch GE, Hensley K, Lawson JA, Marnett LJ, Morrow JD, Murray DM, Plastaras J, Roberts LJ II, Rokach J, Shigenaga MK, Sohal RS, Sun J, Tice RR, VanThiel DH, Wellner D, Walter PB, Tomer KB, Mason RP, Barrett JC. Free Radic. Biol. Med 2005;38:698. [PubMed: 15721980]
11. Kadiiska MB, Gladen BC, Baird DD, Graham LB, Parker CE, Ames BN, Basu S, FitzGerald GA, Lawson JA, Marnett LJ, Morrow JD, Murray DM, Plastaras J, Roberts II LJ, Rokach J, Shigenaga MK, Sun J, Walter PB, Tomer KB, Barrett JC, Mason RP. Free Radic. Biol. Med 2005;38:711. [PubMed: 15721981]
12. Praticò D, Rokach J, Lawson J, FitzGerald GA. Chem. Phys. Lipids 2004;128:165. [PubMed: 15037161]
13. Chang CT, Patel P, Kang N, Lawson JA, Song WL, Powell WS, FitzGerald GA, Rokach J. Bioorg. Med. Chem. Lett 2008;18:5523. [PubMed: 18804370]
14. Song WL, Paschos G, Fries S, Reilly MP, Rokach J, Chang CT, Patel P, Lawson JA, FitzGerald GA. J. Biol. Chem 2009;284:23636. [PubMed: 19520854]
15. Kim S, Lawson JA, Praticò D, FitzGerald GA, Rokach J. Tetrahedron Lett 2002;43:2801.
16. Experimental procedure for Scheme 3a: (Step a) To the solution of acetylene **30** (4 g, 28.54 mmol) in 70 mL benzene was added 1 g of Wilkinson's catalyst (25 wt %) at room temperature. The mixture was purged with argon gas. The deuterium gas was passed in the flask until deuterium gas absorption stopped. The crude mixture was filtered through celite and florisil layers to afford the desired deuterium product **31** in quantitative yields. Sometimes the deuteration did not go to completion. In this case, the crude mixture was filtered and the deuteration process repeated. (Steps b and c) To the solution of deuterium **31** (311 mg, 2.10 mmol) in CH₂Cl₂ (15 mL), Me₂AlCl (6.29 mL, 6.29 mmol) was added dropwise at -25 °C and stirred for 30 min at -25 °C. The reaction mixture was gradually allowed to reach room temperature and the reaction continued for 12 h. After all the starting material was consumed the reaction was quenched using aqueous saturated NaHCO₃ solution at 0 °C. The aqueous layer was extracted with CH₂Cl₂ and the organic layers combined and dried using Na₂SO₄. The solvent was cautiously evaporated up to the point where approximately 2 mL of CH₂Cl₂ was left inside the flask. The deuterium compound **32** was used without further purification in the next step. To the solution of crude alcohol **32**, TsCl was added at 0 °C followed by pyridine and stirred for 10 min. The reaction mixture was gradually allowed to reach room temperature and the stirring continued for 12 h. The reaction was quenched by adding water and extracted using CH₂Cl₂, then dried and purified by silica gel chromatography to afford tosylate **33** in 75% combined yield. (Step d) To the solution of tosylate **33** (660 mg, 3 mmol) in 5 mL of CH₃CN was added Ph₃P (3 g, 11.4 mmol) and the reaction was continued at 70 °C for 24 h. The solvent was evaporated and the crude compound purified using silica gel column chromatography to afford **34** in quantitative yields. (Step e) To the solution of the salt **34** (774 mg, 1.60 mmol) in 15 mL of CH₃CN was added NaI (1.2 g, 8.05 mmol) at room temperature and stirred for 12 h. The solvent was evaporated and the crude mixture purified using column chromatography to afford the desired iodo salt **35** (683 mg) in 97% yield.
17. Spectral data of **d₄-5-*epi*-8,12-iso-iPF_{3a}-VI 55**: ¹H NMR (Methanol-d₄, 400 MHz) δ 5.75 (1H, dd, *J*=15.3, 10.6), 5.44-5.32 (2H, m), 5.28-5.13 (3H, m), 4.09-3.92 (3H, m), 2.72-2.64 (2H, m), 2.57-2.49 (1H, m), 2.36-2.27 (1H, m), 2.26-2.02 (4H, m), 1.77-1.68 (1H, m), 1.68-1.42 (5H, m), 0.81 (1H, s); ¹³C NMR (Methanol-d₄, 100 MHz) δ 177.59, 137.46, 132.48, 130.08, 129.60, 129.41, 128.69, 74.83, 73.09, 72.80, 52.03, 49.86, 43.49, 37.83, 35.13, 26.64, 25.10, 22.37, 13.90(m); spectral data of **d₄-8,12-iso-iPF_{3a}-VI 64**: ¹H NMR (Methanol-d₄, 400 MHz) δ 5.72 (1H, dd, *J*= 15.4, 10.6), 5.47-5.132 (2H, m), 5.27-5.16 (3H, m), 4.05-3.96 (3H, m), 2.75-2.67 (2H, m), 2.56-2.52 (1H, m), 2.38-2.30 (1H, m), 2.22-1.99 (4H, m), 1.78-1.68 (1H, m), 1.63-1.36 (5H, m), 0.81 (1H, s); ¹³C NMR (Methanol-d₄, 100 MHz) δ 177.58, 137.62, 132.65, 131.11, 130.10, 129.59, 128.75, 74.97, 73.96, 72.93, 52.09, 48.63, 43.70, 37.74, 35.06, 26.81, 25.26, 22.41, 13.92(m).
18. Rodriguez A, Nomen M, Spur BW, Godfroid JJ. Tetrahedron Lett 1999;40:5161.

19. Patel P, Chang CT, Kang N, Lee GJ, Powell WS, Rokach J. Tetrahedron Lett 2007;48:5289. [PubMed: 18037973]

Scheme 1.

iPs and nPs derived from AA, EPA, and DHA by free radical peroxidation.

Scheme 2.

Structures of the major EPA-derived iPs 5-*epi*-8,12-*iso*-iPF_{3α}-VI and 8,12-*iso*-iPF_{3α}-VI.

Scheme 3.

Synthesis of deuterated side chain.

Reagents and conditions: a) (a) Wilkinson's catalyst, benzene, D₂, 97%; (b) Me₂AlCl, CH₂Cl₂, -25 °C- rt, 8 h; (c) TsCl, pyridine, CH₂Cl₂, 0 °C- rt, 6 h, 75% (two steps); (d) PPh₃, CH₃CN, 70 °C, 96%; (e) NaI, CH₃CN, rt, 97%; b) (f) KHMDS, THF, -90 °C to rt, 85%; (g) 1N HCl, THF, rt; (h) TsCl, pyridine, CH₂Cl₂, rt, 6 h, 80% (two steps).

Scheme 4.

Stereospecific synthesis of d₄-5-*epi*-8,12-*iso*-iPF_{3α}-VI **55** and d₄-8,12-*iso*-iPF_{3α}-VI **64**

Reagents and conditions: **a)** (i) TESCl, Et₃N, DMAP, CH₂Cl₂, rt, 20 h, 98%; (j) Wilkinson's catalyst, catechol borane, THF, 0 °C to rt, overnight, 91%;¹⁹ (k) PT-SH, Ph₃P, DIAD, THF, 0 °C - rt, 4.5 h, 97%; (l) m-CPBA, NaHCO₃, CH₂Cl₂, rt, overnight, 96%; (m) KHMDS, **48**, DME, -60 °C - rt, 8 h, 52% (*E*: *Z* = 63: 37), separated by silica gel chromatography; (n) NaBH₄, ethylether/MeOH (2:1), rt, 35 min, 70%; (o) TESCl, Et₃N, DMAP, CH₂Cl₂, 20 h, 95%; (p) DMSO, (COCl)₂, Et₃N, CH₂Cl₂, -70 °C to -20 °C, 1.5 h; (q) LiHMDS, **41**, THF, -78 °C to rt, 2 h, (two steps 73%); (r) TBAF, THF, rt, overnight; (s) LiOH, iPrOH/H₂O (1:1), rt, 4 h 93% (two steps); **b)** (t) DMSO, (COCl)₂, Et₃N, CH₂Cl₂, -70 °C to -20 °C, 1.5 h; (u) LiHMDS, **48**, THF, -78 °C to rt, 2 h, (**59**, 8.4%, **60**, 73%) (80% after I₂ treatment); (v) I₂, CH₂Cl₂, rt, 15 h, 87%; (w) EtOH, LiAlH₄, (*S*)-Binal-H, THF, -100 °C, 45 min, 92%; (x) TBDMSCl, Et₃N, DMAP, CH₂Cl₂, rt, overnight, 85%.

Figure 1.

LC/MS/MS chromatograms of d_4 -5-*epi*-8,12-*iso*-iPF_{3 α} -VI **55** and d_4 -8,12-*iso*-iPF_{3 α} -VI **64**. High Performance Liquid Chromatography: The UHPLC was performed using an Accela solvent delivery system (Thermo, Waltham, MA) and a column of Hypersil GOLD C18 (2) (200 mm $\times$ 2.1 mm; 1.9 μ m particle size column; Thermo). The mobile phase consisted of water (solvent A) and acetonitrile:methanol (95:5, solvent B), both with 0.005% acetic acid adjusted to pH 5.7 with ammonium hydroxide. The flow rate was 350 μ l/min. The separations involved various linear solvent gradient programs.

Scheme 5.
 β -oxidation of neuroprostane to EPA-derived isoprostane.